Inovio's UCa-001 trial completes; results posted for INO-5401 combo in urothelial carcinoma

Inovio Pharmaceuticals had one notable registry update this week involving its DNA-based immunotherapy program.

• INO-5401 and INO-9012, administered with atezolizumab, is a Phase I/IIA open-label trial in locally advanced unresectable or metastatic/recurrent Urothelial Carcinoma, evaluating safety, immunogenicity and preliminary clinical efficacy of the combination.¹ The study is listed as completed, with enrollment of 35 participants.¹ Results were first posted to the registry on 2026-09-02, though the record does not indicate when that posting occurred relative to this report.